| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 91 | 2024 | 6915 | 5.800 |
Why?
|
| Myelodysplastic Syndromes | 29 | 2023 | 2979 | 2.680 |
Why?
|
| Mutation | 62 | 2023 | 15179 | 2.340 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 28 | 2024 | 923 | 2.130 |
Why?
|
| Isocitrate Dehydrogenase | 12 | 2023 | 480 | 1.830 |
Why?
|
| Neoplasms, Second Primary | 10 | 2022 | 1350 | 1.700 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 13 | 2023 | 801 | 1.620 |
Why?
|
| Clonal Evolution | 8 | 2023 | 253 | 1.500 |
Why?
|
| Hematopoiesis | 9 | 2024 | 560 | 1.490 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 9 | 2023 | 426 | 1.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2022 | 15862 | 1.410 |
Why?
|
| Antineoplastic Agents | 26 | 2023 | 14289 | 1.210 |
Why?
|
| Sulfonamides | 27 | 2024 | 1823 | 1.190 |
Why?
|
| DNA Methylation | 7 | 2023 | 2669 | 1.170 |
Why?
|
| Myeloproliferative Disorders | 6 | 2024 | 767 | 1.150 |
Why?
|
| Azacitidine | 13 | 2023 | 1149 | 0.990 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2022 | 3552 | 0.900 |
Why?
|
| Aged | 96 | 2024 | 70117 | 0.890 |
Why?
|
| Humans | 177 | 2024 | 261506 | 0.890 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 5 | 2022 | 505 | 0.890 |
Why?
|
| Protein Kinase Inhibitors | 16 | 2022 | 4757 | 0.850 |
Why?
|
| Clone Cells | 3 | 2018 | 555 | 0.820 |
Why?
|
| Middle Aged | 91 | 2023 | 86204 | 0.810 |
Why?
|
| Cytarabine | 14 | 2023 | 1973 | 0.800 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2022 | 113 | 0.790 |
Why?
|
| Thalidomide | 2 | 2022 | 569 | 0.770 |
Why?
|
| Aged, 80 and over | 55 | 2022 | 29902 | 0.760 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 10 | 2023 | 2527 | 0.740 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 5 | 2024 | 217 | 0.740 |
Why?
|
| Propensity Score | 6 | 2022 | 750 | 0.730 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 1664 | 0.720 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 4 | 2023 | 197 | 0.720 |
Why?
|
| Nuclear Proteins | 13 | 2023 | 3343 | 0.720 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2021 | 2390 | 0.700 |
Why?
|
| Idarubicin | 5 | 2022 | 446 | 0.690 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2022 | 2796 | 0.690 |
Why?
|
| Hematologic Neoplasms | 6 | 2022 | 1870 | 0.680 |
Why?
|
| Biomarkers, Tumor | 13 | 2021 | 10331 | 0.670 |
Why?
|
| Adult | 72 | 2022 | 77950 | 0.670 |
Why?
|
| Male | 88 | 2024 | 123000 | 0.660 |
Why?
|
| Dioxygenases | 4 | 2024 | 159 | 0.640 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 52 | 0.630 |
Why?
|
| Female | 90 | 2024 | 141928 | 0.630 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3230 | 0.630 |
Why?
|
| Prognosis | 36 | 2024 | 21713 | 0.620 |
Why?
|
| Dasatinib | 8 | 2022 | 862 | 0.620 |
Why?
|
| High-Throughput Nucleotide Sequencing | 15 | 2023 | 2291 | 0.610 |
Why?
|
| Germ Cells | 2 | 2020 | 335 | 0.610 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2021 | 5178 | 0.600 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2022 | 560 | 0.600 |
Why?
|
| Remission Induction | 16 | 2022 | 3569 | 0.590 |
Why?
|
| Bone Marrow | 14 | 2023 | 2358 | 0.590 |
Why?
|
| Survival Rate | 23 | 2023 | 12221 | 0.580 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2015 | 24 | 0.540 |
Why?
|
| Chemokine CCL4 | 1 | 2015 | 63 | 0.540 |
Why?
|
| Chemokine CCL3 | 1 | 2015 | 63 | 0.530 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2023 | 2488 | 0.520 |
Why?
|
| ras Proteins | 3 | 2022 | 770 | 0.520 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2020 | 2359 | 0.510 |
Why?
|
| GTP Phosphohydrolases | 2 | 2016 | 336 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 10035 | 0.490 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2024 | 1242 | 0.490 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 1879 | 0.490 |
Why?
|
| Recurrence | 11 | 2022 | 4758 | 0.480 |
Why?
|
| Stem Cells | 1 | 2021 | 1213 | 0.480 |
Why?
|
| Philadelphia Chromosome | 7 | 2022 | 793 | 0.480 |
Why?
|
| Genomics | 5 | 2020 | 2738 | 0.470 |
Why?
|
| Follow-Up Studies | 24 | 2021 | 14889 | 0.470 |
Why?
|
| Young Adult | 29 | 2022 | 21445 | 0.470 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 460 | 0.470 |
Why?
|
| Single-Cell Analysis | 4 | 2021 | 470 | 0.460 |
Why?
|
| Primary Myelofibrosis | 4 | 2018 | 831 | 0.460 |
Why?
|
| Germ-Line Mutation | 6 | 2020 | 1046 | 0.450 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 1450 | 0.450 |
Why?
|
| Chromosome Deletion | 3 | 2021 | 1005 | 0.450 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 305 | 0.450 |
Why?
|
| Sequence Analysis, DNA | 7 | 2023 | 2483 | 0.440 |
Why?
|
| Aminopyridines | 4 | 2022 | 212 | 0.440 |
Why?
|
| Oxazines | 1 | 2012 | 43 | 0.440 |
Why?
|
| Pyelonephritis | 1 | 2012 | 39 | 0.440 |
Why?
|
| Mutant Proteins | 1 | 2013 | 234 | 0.430 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2016 | 430 | 0.430 |
Why?
|
| Triazines | 3 | 2022 | 117 | 0.430 |
Why?
|
| Fluoroquinolones | 1 | 2012 | 126 | 0.410 |
Why?
|
| Neoplasms | 11 | 2024 | 15193 | 0.410 |
Why?
|
| Leukemia, Myeloid | 4 | 2021 | 941 | 0.410 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 259 | 0.400 |
Why?
|
| Repressor Proteins | 5 | 2021 | 1664 | 0.400 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 482 | 0.390 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 943 | 0.390 |
Why?
|
| Combined Modality Therapy | 6 | 2021 | 8865 | 0.390 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1331 | 0.390 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2023 | 461 | 0.380 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 388 | 0.380 |
Why?
|
| Janus Kinase 2 | 2 | 2019 | 679 | 0.380 |
Why?
|
| Cell Nucleus | 1 | 2016 | 1620 | 0.370 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 13 | 2022 | 6550 | 0.370 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 1258 | 0.360 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2019 | 1094 | 0.360 |
Why?
|
| Retrospective Studies | 31 | 2024 | 37905 | 0.350 |
Why?
|
| Treatment Outcome | 31 | 2022 | 32848 | 0.350 |
Why?
|
| DNA-Binding Proteins | 6 | 2024 | 4821 | 0.350 |
Why?
|
| Induction Chemotherapy | 3 | 2022 | 669 | 0.320 |
Why?
|
| Cohort Studies | 9 | 2024 | 9244 | 0.320 |
Why?
|
| Epigenesis, Genetic | 5 | 2023 | 1399 | 0.320 |
Why?
|
| Benzimidazoles | 3 | 2022 | 428 | 0.310 |
Why?
|
| Disease-Free Survival | 14 | 2020 | 10001 | 0.300 |
Why?
|
| Drug Administration Schedule | 10 | 2020 | 3472 | 0.290 |
Why?
|
| Survival Analysis | 12 | 2020 | 9180 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2021 | 6207 | 0.280 |
Why?
|
| Gene Frequency | 5 | 2021 | 1163 | 0.280 |
Why?
|
| Membrane Proteins | 2 | 2016 | 2819 | 0.280 |
Why?
|
| Translocation, Genetic | 4 | 2023 | 1245 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2021 | 234 | 0.280 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 4638 | 0.270 |
Why?
|
| Radiotherapy | 1 | 2013 | 1824 | 0.270 |
Why?
|
| Vidarabine | 6 | 2022 | 1341 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2024 | 1493 | 0.270 |
Why?
|
| Genes, p53 | 2 | 2022 | 1090 | 0.270 |
Why?
|
| Artificial Intelligence | 2 | 2020 | 388 | 0.270 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 1146 | 0.270 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 3 | 2023 | 310 | 0.260 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2018 | 221 | 0.250 |
Why?
|
| Transcription Factors | 5 | 2023 | 5270 | 0.250 |
Why?
|
| Adolescent | 21 | 2021 | 31252 | 0.250 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 905 | 0.240 |
Why?
|
| Chromosome Inversion | 2 | 2023 | 182 | 0.240 |
Why?
|
| Blood Platelet Disorders | 1 | 2024 | 37 | 0.240 |
Why?
|
| Imatinib Mesylate | 3 | 2019 | 1665 | 0.230 |
Why?
|
| Doxorubicin | 6 | 2021 | 3005 | 0.230 |
Why?
|
| Cell Cycle Proteins | 3 | 2023 | 2045 | 0.230 |
Why?
|
| Histone Demethylases | 2 | 2023 | 144 | 0.230 |
Why?
|
| Dexamethasone | 7 | 2022 | 1450 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 3251 | 0.230 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 2 | 2021 | 118 | 0.220 |
Why?
|
| Piperidines | 5 | 2021 | 1035 | 0.220 |
Why?
|
| Adenine | 4 | 2021 | 631 | 0.220 |
Why?
|
| Antigens, CD19 | 2 | 2023 | 577 | 0.220 |
Why?
|
| Pyrimidines | 5 | 2019 | 3518 | 0.220 |
Why?
|
| Daunorubicin | 2 | 2020 | 301 | 0.210 |
Why?
|
| Glycine | 2 | 2021 | 289 | 0.210 |
Why?
|
| Gene Rearrangement | 2 | 2023 | 783 | 0.210 |
Why?
|
| Models, Biological | 3 | 2020 | 3254 | 0.210 |
Why?
|
| Alleles | 3 | 2019 | 2437 | 0.210 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2022 | 71 | 0.210 |
Why?
|
| Salvage Therapy | 5 | 2021 | 2054 | 0.210 |
Why?
|
| Acute Disease | 6 | 2024 | 2422 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 2 | 2012 | 2992 | 0.200 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2021 | 14 | 0.200 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 846 | 0.200 |
Why?
|
| WT1 Proteins | 1 | 2022 | 106 | 0.200 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2021 | 49 | 0.190 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 132 | 0.190 |
Why?
|
| Antibodies, Bispecific | 2 | 2022 | 246 | 0.190 |
Why?
|
| Neoplasm, Residual | 6 | 2022 | 1656 | 0.190 |
Why?
|
| Exanthema | 2 | 2020 | 211 | 0.190 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 173 | 0.190 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 2021 | 88 | 0.190 |
Why?
|
| Pyrazoles | 3 | 2019 | 1471 | 0.190 |
Why?
|
| Leukemia | 2 | 2020 | 1635 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 247 | 0.180 |
Why?
|
| Tandem Repeat Sequences | 3 | 2020 | 201 | 0.180 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 1299 | 0.180 |
Why?
|
| Genes, ras | 3 | 2022 | 667 | 0.180 |
Why?
|
| Pyridines | 3 | 2021 | 1244 | 0.180 |
Why?
|
| Core Binding Factors | 2 | 2022 | 112 | 0.180 |
Why?
|
| Siblings | 1 | 2021 | 285 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2020 | 108 | 0.180 |
Why?
|
| HIV Infections | 1 | 2012 | 2134 | 0.180 |
Why?
|
| Multigene Family | 1 | 2021 | 425 | 0.180 |
Why?
|
| Megakaryocyte-Erythroid Progenitor Cells | 1 | 2019 | 5 | 0.180 |
Why?
|
| Epigenomics | 1 | 2021 | 266 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2023 | 2232 | 0.180 |
Why?
|
| Karyotype | 4 | 2022 | 234 | 0.170 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2020 | 113 | 0.170 |
Why?
|
| Biological Products | 1 | 2022 | 274 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2020 | 311 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 665 | 0.170 |
Why?
|
| Neoplasm Staging | 5 | 2016 | 13658 | 0.170 |
Why?
|
| Signal Transduction | 5 | 2021 | 11965 | 0.170 |
Why?
|
| Protein Phosphatase 2C | 1 | 2018 | 75 | 0.160 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 479 | 0.160 |
Why?
|
| Cyclophosphamide | 6 | 2021 | 3001 | 0.160 |
Why?
|
| Microfluidics | 1 | 2018 | 33 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2020 | 272 | 0.160 |
Why?
|
| Mice | 13 | 2024 | 34495 | 0.160 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 2138 | 0.160 |
Why?
|
| Animals | 16 | 2024 | 59536 | 0.160 |
Why?
|
| Heterografts | 1 | 2020 | 733 | 0.160 |
Why?
|
| Anemia | 1 | 2024 | 689 | 0.160 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 114 | 0.160 |
Why?
|
| Drug Evaluation | 2 | 2020 | 425 | 0.160 |
Why?
|
| Retreatment | 2 | 2016 | 452 | 0.160 |
Why?
|
| Risk Factors | 7 | 2024 | 17523 | 0.160 |
Why?
|
| Age Factors | 7 | 2020 | 5377 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4744 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 5539 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2019 | 158 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 224 | 0.150 |
Why?
|
| Prospective Studies | 9 | 2024 | 12873 | 0.150 |
Why?
|
| Rituximab | 2 | 2021 | 1528 | 0.150 |
Why?
|
| Mycoses | 1 | 2021 | 386 | 0.150 |
Why?
|
| Arabinonucleosides | 2 | 2021 | 437 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 810 | 0.150 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 834 | 0.150 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2016 | 18 | 0.140 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 14551 | 0.140 |
Why?
|
| Time Factors | 6 | 2019 | 12926 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 895 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 1516 | 0.140 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2017 | 118 | 0.140 |
Why?
|
| Models, Genetic | 1 | 2020 | 1113 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 3 | 2022 | 2330 | 0.140 |
Why?
|
| PC12 Cells | 1 | 2016 | 46 | 0.140 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 1084 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1763 | 0.140 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2015 | 24 | 0.130 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2015 | 42 | 0.130 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 106 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 252 | 0.130 |
Why?
|
| Vincristine | 4 | 2021 | 1511 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2019 | 3033 | 0.130 |
Why?
|
| Computational Biology | 1 | 2021 | 1271 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2019 | 649 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2015 | 74 | 0.130 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 254 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 259 | 0.130 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2016 | 160 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1048 | 0.130 |
Why?
|
| Telomere-Binding Proteins | 1 | 2015 | 85 | 0.130 |
Why?
|
| Mesoderm | 1 | 2017 | 404 | 0.130 |
Why?
|
| RNA Splicing Factors | 1 | 2015 | 153 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2022 | 749 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2021 | 1360 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 280 | 0.120 |
Why?
|
| Mitochondria | 1 | 2021 | 1282 | 0.120 |
Why?
|
| Adenine Nucleotides | 1 | 2015 | 351 | 0.120 |
Why?
|
| Transplantation Conditioning | 2 | 2021 | 2238 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2016 | 829 | 0.120 |
Why?
|
| Patients | 1 | 2016 | 245 | 0.120 |
Why?
|
| Protein Transport | 1 | 2016 | 734 | 0.120 |
Why?
|
| Gene Expression | 3 | 2016 | 3570 | 0.120 |
Why?
|
| Chromosome Aberrations | 3 | 2018 | 1960 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2019 | 1544 | 0.110 |
Why?
|
| Cytogenetics | 1 | 2013 | 149 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2016 | 2074 | 0.110 |
Why?
|
| Graft vs Host Disease | 2 | 2021 | 2638 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2018 | 5637 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 1085 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2016 | 641 | 0.110 |
Why?
|
| Nucleosomes | 1 | 2013 | 143 | 0.110 |
Why?
|
| Exome | 2 | 2015 | 1239 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 1910 | 0.110 |
Why?
|
| Transcriptome | 4 | 2023 | 1859 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 1489 | 0.100 |
Why?
|
| Family | 1 | 2016 | 736 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 3869 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 1823 | 0.100 |
Why?
|
| Thrombocythemia, Essential | 1 | 2013 | 162 | 0.100 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 644 | 0.100 |
Why?
|
| RNA Interference | 1 | 2016 | 1408 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2295 | 0.100 |
Why?
|
| Cisplatin | 1 | 2018 | 2432 | 0.100 |
Why?
|
| Virulence Factors | 1 | 2012 | 213 | 0.100 |
Why?
|
| Gene Duplication | 1 | 2013 | 421 | 0.100 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 249 | 0.100 |
Why?
|
| Polycythemia Vera | 1 | 2013 | 238 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1945 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 2195 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 1085 | 0.090 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 241 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2015 | 755 | 0.090 |
Why?
|
| Incidence | 2 | 2019 | 5673 | 0.090 |
Why?
|
| Cell Communication | 1 | 2013 | 509 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2016 | 6100 | 0.090 |
Why?
|
| Urinary Tract Infections | 2 | 2005 | 321 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2018 | 1423 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1143 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 418 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2018 | 1589 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2015 | 1152 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 4938 | 0.090 |
Why?
|
| Receptor, Notch1 | 2 | 2022 | 218 | 0.090 |
Why?
|
| Entropy | 1 | 2009 | 37 | 0.090 |
Why?
|
| Antifungal Agents | 3 | 2021 | 834 | 0.090 |
Why?
|
| Cladribine | 2 | 2022 | 233 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 4988 | 0.080 |
Why?
|
| Sex Factors | 4 | 2020 | 2139 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2013 | 825 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 11538 | 0.080 |
Why?
|
| Heparin | 1 | 2011 | 360 | 0.080 |
Why?
|
| Texas | 2 | 2016 | 6311 | 0.080 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4654 | 0.080 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 568 | 0.080 |
Why?
|
| Escherichia coli | 2 | 2012 | 1203 | 0.080 |
Why?
|
| Comorbidity | 3 | 2024 | 2352 | 0.080 |
Why?
|
| Aging | 2 | 2009 | 1582 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2019 | 7226 | 0.080 |
Why?
|
| Visual Perception | 1 | 2009 | 154 | 0.080 |
Why?
|
| Spleen | 2 | 2024 | 676 | 0.080 |
Why?
|
| Photic Stimulation | 1 | 2009 | 259 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2016 | 4804 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2016 | 2022 | 0.080 |
Why?
|
| Rats | 1 | 2016 | 6086 | 0.070 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2010 | 362 | 0.070 |
Why?
|
| Proteolysis | 2 | 2020 | 370 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2018 | 2292 | 0.070 |
Why?
|
| Graft Survival | 1 | 2010 | 1062 | 0.070 |
Why?
|
| DNA Repair | 2 | 2024 | 1872 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 4298 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2011 | 787 | 0.070 |
Why?
|
| Nitriles | 2 | 2021 | 906 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2018 | 6869 | 0.060 |
Why?
|
| Fractals | 1 | 2004 | 11 | 0.060 |
Why?
|
| Genome, Human | 1 | 2013 | 1869 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1586 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2009 | 621 | 0.060 |
Why?
|
| Neutropenia | 2 | 2019 | 968 | 0.060 |
Why?
|
| Karyotyping | 2 | 2017 | 1022 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2015 | 2967 | 0.060 |
Why?
|
| Electroencephalography | 1 | 2009 | 898 | 0.060 |
Why?
|
| Risk | 2 | 2020 | 1972 | 0.060 |
Why?
|
| Erythroid Cells | 1 | 2024 | 49 | 0.060 |
Why?
|
| Georgia | 1 | 2023 | 53 | 0.060 |
Why?
|
| Pedigree | 2 | 2019 | 1890 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2023 | 118 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 6009 | 0.060 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2002 | 11 | 0.060 |
Why?
|
| Ofloxacin | 1 | 2002 | 41 | 0.060 |
Why?
|
| Disease Progression | 3 | 2021 | 6682 | 0.050 |
Why?
|
| Lactams | 1 | 2002 | 24 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4320 | 0.050 |
Why?
|
| Levofloxacin | 1 | 2002 | 57 | 0.050 |
Why?
|
| Income | 1 | 2023 | 222 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2024 | 4078 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5319 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 170 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2022 | 62 | 0.050 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2002 | 60 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 2283 | 0.050 |
Why?
|
| Capsid | 1 | 2002 | 103 | 0.050 |
Why?
|
| Aminoglycosides | 1 | 2022 | 220 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2002 | 210 | 0.050 |
Why?
|
| Granzymes | 1 | 2021 | 91 | 0.050 |
Why?
|
| Splicing Factor U2AF | 1 | 2021 | 48 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 434 | 0.050 |
Why?
|
| NAD | 1 | 2021 | 89 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 324 | 0.050 |
Why?
|
| Algorithms | 2 | 2023 | 3890 | 0.050 |
Why?
|
| Capsid Proteins | 1 | 2002 | 185 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2023 | 435 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2020 | 16273 | 0.050 |
Why?
|
| Azoles | 1 | 2021 | 47 | 0.050 |
Why?
|
| Phylogeny | 1 | 2023 | 826 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2021 | 57 | 0.050 |
Why?
|
| Mercaptopurine | 1 | 2021 | 130 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2020 | 39 | 0.050 |
Why?
|
| HL-60 Cells | 1 | 2021 | 302 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 1217 | 0.050 |
Why?
|
| Iron | 1 | 2024 | 376 | 0.050 |
Why?
|
| Asparaginase | 1 | 2021 | 184 | 0.050 |
Why?
|
| Glutamine | 1 | 2022 | 299 | 0.050 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2020 | 41 | 0.050 |
Why?
|
| Doxycycline | 1 | 2021 | 178 | 0.050 |
Why?
|
| Consolidation Chemotherapy | 1 | 2020 | 155 | 0.050 |
Why?
|
| Phenotype | 2 | 2023 | 6295 | 0.050 |
Why?
|
| Body Surface Area | 1 | 2020 | 42 | 0.050 |
Why?
|
| Child | 5 | 2020 | 29154 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 6942 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2020 | 189 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8873 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 253 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2002 | 429 | 0.040 |
Why?
|
| Prodrugs | 1 | 2021 | 217 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2002 | 368 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5061 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2020 | 8223 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2023 | 1144 | 0.040 |
Why?
|
| Pyridazines | 1 | 2022 | 293 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2023 | 3341 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2024 | 731 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 650 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2021 | 614 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 87 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2022 | 1313 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 2594 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 65 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 582 | 0.040 |
Why?
|
| Prednisone | 1 | 2021 | 984 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2021 | 837 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2021 | 668 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 3639 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 1290 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 486 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2021 | 5710 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 166 | 0.040 |
Why?
|
| Methotrexate | 1 | 2021 | 999 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 669 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2018 | 181 | 0.040 |
Why?
|
| Oncogene Protein p55(v-myc) | 1 | 2017 | 19 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 201 | 0.040 |
Why?
|
| Luciferases | 2 | 2013 | 445 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 5047 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 1869 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 769 | 0.040 |
Why?
|
| Infant | 3 | 2020 | 13310 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 566 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2017 | 142 | 0.040 |
Why?
|
| Triazoles | 1 | 2021 | 617 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2015 | 2307 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 465 | 0.040 |
Why?
|
| SMARCB1 Protein | 1 | 2017 | 109 | 0.040 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2016 | 24 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1681 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 1538 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2002 | 1459 | 0.040 |
Why?
|
| Colitis | 1 | 2019 | 340 | 0.030 |
Why?
|
| Imidazoles | 1 | 2022 | 999 | 0.030 |
Why?
|
| Homeostasis | 1 | 2021 | 950 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 1077 | 0.030 |
Why?
|
| beta Catenin | 1 | 2020 | 688 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2019 | 383 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2021 | 1385 | 0.030 |
Why?
|
| Apoptosis | 2 | 2021 | 7591 | 0.030 |
Why?
|
| DNA Damage | 1 | 2024 | 1954 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 1052 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2018 | 485 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2019 | 498 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2022 | 1085 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2021 | 1171 | 0.030 |
Why?
|
| Itraconazole | 1 | 2015 | 77 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2017 | 204 | 0.030 |
Why?
|
| Codon | 1 | 2015 | 241 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2015 | 169 | 0.030 |
Why?
|
| Genes, myc | 1 | 2017 | 358 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 750 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 524 | 0.030 |
Why?
|
| Mosaicism | 1 | 2017 | 272 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 677 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 275 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 245 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2015 | 290 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2016 | 245 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2016 | 6150 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2015 | 254 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 1506 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1489 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2015 | 289 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 660 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 519 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2018 | 712 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 842 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2016 | 380 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 589 | 0.030 |
Why?
|
| Interphase | 1 | 2013 | 145 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2016 | 5395 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 1443 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2019 | 1555 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 848 | 0.030 |
Why?
|
| Chromosomes | 1 | 2013 | 244 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2013 | 223 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3821 | 0.030 |
Why?
|
| Fatigue | 1 | 2018 | 1239 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2017 | 1152 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 1058 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 719 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 518 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2013 | 185 | 0.030 |
Why?
|
| New York City | 1 | 2011 | 74 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 2803 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2017 | 1353 | 0.020 |
Why?
|
| Brain | 1 | 2004 | 4113 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 269 | 0.020 |
Why?
|
| Mitosis | 1 | 2013 | 615 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 2055 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 929 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2016 | 899 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 671 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 3443 | 0.020 |
Why?
|
| Platelet Count | 1 | 2011 | 490 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 3441 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2010 | 307 | 0.020 |
Why?
|
| Evoked Potentials, Visual | 1 | 2009 | 39 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 4367 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 1946 | 0.020 |
Why?
|
| Sensation | 1 | 2009 | 71 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 1756 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 3719 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2013 | 1529 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2009 | 209 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2010 | 384 | 0.020 |
Why?
|
| Transfection | 1 | 2013 | 2944 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 1581 | 0.020 |
Why?
|
| Melphalan | 1 | 2010 | 834 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7548 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3045 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 3536 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4892 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2009 | 304 | 0.020 |
Why?
|
| Busulfan | 1 | 2010 | 764 | 0.020 |
Why?
|
| Enterococcus faecalis | 1 | 2005 | 49 | 0.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 1724 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 2961 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2005 | 218 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2004 | 60 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 418 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5159 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2011 | 945 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2005 | 233 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2005 | 374 | 0.010 |
Why?
|
| beta-Lactams | 1 | 2002 | 53 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 3842 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 2083 | 0.010 |
Why?
|
| Receptors, Virus | 1 | 2002 | 157 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2004 | 644 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2004 | 1178 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2002 | 471 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2002 | 716 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 1648 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 1694 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2002 | 1616 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 7702 | 0.000 |
Why?
|